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Abstract
Musculoskeletal pain (MSP) is a common sequela of traumatic stress exposure. While biologic 
factors contributing to chronic MSP after motor vehicle collision (MVC) have traditionally 
focused on tissue injury, increasing evidence suggests that neuro/stress/immune processes 
mediated by stress system activation may play a more dominant role. In a previous study we found 
that genetic variants in the hypothalamic-pituitary-adrenal (HPA) axis-related gene FKBP5 
influence vulnerability to persistent MSP 6 weeks after MVC. In the present cohort study (n = 
855) we evaluated whether genetic variants in several other important HPA axis-related genes, 
including the glucocorticoid receptor (NR3C1), corticotropin-releasing hormone receptor R1 
(CRHR1), and corticotropin-releasing hormone binding protein (CRHBP), influence risk of 
chronic MSP over time after MVC. Genetic polymorphism rs7718461 in the CRHBP gene showed 
significant association (p=0.0012) with overall pain severity during the year after MVC in 
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regression models controlling for multiple comparisons. Two additional CRHBP alleles in high 
Linkage Disequilibrium with rs7718461 also showed trend-level significance. In secondary 
analyses, a significant interaction between this CRHBP locus (Minor Allele Frequency = 0.33) and 
time was observed (p = 0.015), with increasing effect observed over time following trauma. A 
significant CRHBP*FKBP5 interaction was also observed, with substantially increased MSP after 
MVC in those with a risk allele in both genes compared to either gene alone. The results of this 
study indicate that genetic variants in two different HPA axis genes predict chronic MSP severity 
following MVC, and support the hypothesis that the HPA axis is involved in chronic post-MVC 
MSP pathogenesis.
Keywords
Genetic variant; CRHBP; HPA axis; musculoskeletal pain; stress induced hyperalgesia; motor 
vehicle collision
 INTRODUCTION
More than 50 million motor vehicle collisions (MVCs) occur worldwide, and more than 
eleven million Americans experience an MVC each year [1]. The vast majority of 
individuals experiencing MVC do not have identifiable acute injury, however chronic 
musculoskeletal pain (MSP) is commonly reported by survivors of such events[25] and 
results in substantial suffering and diminished health[22; 51].
The pathobiology of chronic MSP development after MVC remains poorly understood. 
Collision characteristics are poor predictors of MSP outcomes[24; 37]; these data and other 
lines of evidence indicate that tissue injury is not a dominant factor determining post-MVC 
MSP outcomes[35]. In contrast, increasing evidence suggests that physiologic systems 
which shape stress and neuro-immune responses, such as the hypothalamic-pituitary-adrenal 
(HPA) axis, may play an important role in influencing MSP outcomes after traumatic/
stressful events such as MVC[10; 26; 34; 35; 53; 54].
If the HPA axis influences the development of chronic MSP after MVC, then genetic 
variants affecting key proteins modulating HPA axis function should be associated with 
vulnerability to chronic post-MVC MSP. In a previous study we found an association 
between genetic variants in the gene coding for FK506 binding protein 51 (FKBP5), an 
important regulator of hypothalamic-pituitary-adrenal (HPA) axis function[12], and MSP 
severity 6 weeks after MVC[10]. In this study we evaluated the association between post-
MVC MSP and three other important HPA axis-related genes: the glucocorticoid receptor 
(NR3C1), corticotropin-releasing hormone (CRH) receptor 1 (CRHR1), and CRH binding 
protein (CRHBP). In addition, because of increasing evidence that genetic influences on 
pain outcomes after stress exposure are often time[15] and/or sex[38]-dependent, in 
secondary analyses we assessed for interactions between significant main effects and sex 
and time. Also, because of evidence that HPA gene effects may be interactive[16; 45; 46], 
we explored for interactions between main effects and the previously identified FKBP5 risk 
allele[10].
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 METHODS
 Study design and population
The details of the MVC study have been reported[44]. In brief, individuals ≥ 18 and ≤ 65 
years of age presenting to one of eight Emergency Departments (ED) in four no-fault 
insurance states within 24 hours of MVC who did not have fracture or other injury requiring 
hospital admission were enrolled. Patients who were not alert and oriented were excluded, as 
were pregnant patients, prisoners, patients unable to read and understand English, or patients 
taking opioids above a total daily dose of 30 mg of oral morphine or equivalent. In addition, 
because genetic analyses are potentially biased by population stratification, enrollment was 
limited to non-Hispanic whites (the most common ethnicity at study sites). Informed consent 
was obtained from all participants and Institutional Review Board (IRB) approval was 
obtained at all study sites.
 DNA collection and genotyping
A blood sample (PAXgene DNA tube) was collected at the time of study enrollment. 
Following DNA purification (PAXgene blood DNA kit, QIAGEN), genotyping was 
performed using the Sequenom platform. Sixteen Single Nucleotide Polymorphisms (SNPs) 
were genotyped across CRHBP, CRHR1, and NR3C1 (Figure 1). These SNPs were selected 
because they have previously been associated with neuropsychiatric diseases or pain 
outcomes[23; 28; 31] or because they are tagging SNPs. Two Hapmap samples and two 
repeat samples were included in each genotyping batch (96 samples) to ensure genotypic 
accuracy and reliability.
 Assessments
Sociodemographic information was collected at the time of the ED visit using a structured 
interview. Overall pain intensity in the ED and average pain during the month prior to MVC 
were each assessed by research assistants at the time of the ED interview using a verbal 0–
10 numeric rating scale (NRS). Verbal scores have advantages in acute care settings, and 
verbally administered NRSs have been validated as a substitute for visual analogue scales in 
acute pain measurement in the ED[5]. Participant follow-up evaluations were conducted six 
weeks, six months, and one year after MVC using a web-based questionnaire or telephone 
interview. Each evaluation included an assessment of overall pain intensity in the past week 
(0–10 NRS); this assessment was used as the primary study outcome measure.
 Analyses
Linkage disequilibrium between SNPs in CRHBP, CRHR1, and NR3C1 were explored by 
calculating Levontin D’ and squared correlation r2 using HaploView[2]. Associations 
between polymorphisms in CRHBP, CRHR1 and NR3C1 and overall pain intensity in the 
past week, at 6 weeks, 6 months, and 1 year were assessed using a repeated measures mixed 
model. Based on the results of previous studies[9; 10; 30; 36], study site, sex, past pain 
severity, and time from trauma in weeks were included in the model as covariates. Multiple 
testing was controlled for using the method of principal components[39]. Haplotype 
frequencies were calculated for the eight possible haplotypes with CRHBP SNPs using the 
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expectation-maximization algorithm implemented in HaploView and verified using Bayesian 
estimation of haplotype frequencies implemented in SAS 9.2[29]. As described below, the 
three SNPs genotyped from the CRHBP genomic region were in high linkage disequilibrium 
(D’ ≥ 0.97, Figure 1), and therefore were evaluated as a haplotype. Consistent with previous 
evidence[46], a dominant model of CRHBP effect provided the best fit to the data and was 
employed. Interactions between CRHBP haplotypes, sex, time from trauma (in weeks), and 
FKBP5 allele were assessed by including the corresponding product terms in the models. 
Based on the results of previous studies, FKBP5 tagging SNP rs3800373 was used as the 
FKBP5 risk allele[10; 20]. Analyses were performed using SAS 9.2 (SAS Institute Inc, 
Cary, NC).
 RESULTS
 Participants
Baseline characteristics of study participants are shown in Table 1. A total of 949 European 
Americans were enrolled in the study. Most study participants were women less than 40 
years of age with some post-secondary education.
 Genotyping results
All 16 selected SNPs were successfully genotyped. Genotyped SNPs were in Hardy-
Weinberg equilibrium (p > 0.05) and had excellent call rates (≥99%).
 Association of HPA-related SNPs with overall MSP 6 weeks, 6 months, and 1 year after 
MVC
Eight hundred and fifty five of 949 individuals (90%) completed pain assessments at all 
three timepoints following MVC and were included in the analyses. Results of analyses 
evaluating the association between HPA axis-related SNPs and MSP outcomes after MVC 
are shown in Table 2. All three CRHBP SNPs assessed (rs7718461, rs1875999, and 
rs1053989) were associated with MSP after MVC at the trend-level (p < .01), and one of 
these SNPs, CRHBP SNP rs7718461, was significantly associated with post-MVC pain 
burden after adjustment for multiple testing (Table 2). With each of these CRHBP SNPs, the 
minor allele was associated with increased chronic MSP severity. The FKBP5 tagging SNP, 
rs3800373, which was previously shown to be associated with MSP severity 6 weeks 
following MVC[10], was also significantly associated with chronic MSP severity across 
time in the present study, with the minor allele associated with worse MSP outcomes (Table 
2).
 Secondary analyses
 Evaluation for potential gene-time interactions—Because all three CRHBP SNPs 
were in very high Linkage Disequilibrium (LD), and because the minor allele of each SNP 
was associated with pain vulnerability, subsequent analyses were performed with the three 
CRHBP SNPs grouped into a haplotype. Of eight possible haplotypes constituted from the 
three SNPs, only H1, H2, and H3 had frequencies above 0.01 (Supplementary Table 1). H2 
contained all three CRHBP risk alleles (G-G-T, frequency = 0.33); in a repeated measures 
mixed model, H2 haplotype was significantly associated with post-MVC pain severity after 
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adjustment for assessment week and study site (F(1,900)=7.7, p=0.006). Therefore the H2 
haplotype was utilized in subsequent analyses.
Because of evidence that genetic influences on pain outcomes after stress exposure are often 
time-dependent,15 we assessed for time-dependent differences in the influence of CRHBP 
H2 haplotype on post-MVC MSP severity, and in the influence of FKBP5 allele rs3800373 
on post-MVC MSP severity. A significant time-CRHBP H2 haplotype effect was observed 
(F(1,897)=5.9, p=0.015, Table 3, Figure 2 Panel A), with the presence of a CRHBP H2 
haplotype minor allele having an increasing effect with increasing time from trauma. No 
evidence for an interaction was observed between FKBP5 allele rs3800373 and time 
(F(1,897)=0.28, p=0.40, Table 3). These results are also presented in graphical format in 
Panel A of Figure 2.
 Evaluation for potential gene-sex interactions—As described above, because of 
evidence that genetic influences on pain outcomes after stress exposure are often sex-
dependent14,32,33, we also evaluated for an interaction between sex and H2 haplotype and 
chronic post-MVC MSP severity. CRHBP analyses were stratified by timepoint because of 
the above evidence that CRHBP effects are time-dependent. No interaction was observed 
(F(1,843)=0.21, p=0.65 at 6 weeks; F(1,822)=1.73, p=0.19 at 6 months; F(1,842)=0.76, 
p=0.38 at 1 year). Similarly, no interaction was observed between sex and FKBP5 allele 
rs3800373 and pain over time after MVC (F(1,843)=0.66, p=0.42).
 Evaluation for potential gene-gene interactions—In addition, because of previous 
evidence that HPA gene effects may be interactive[16; 45; 46], we tested for an interaction 
between the FKBP5 genotype rs3800373 and CRHBP H2 haplotype. CRHBP analyses were 
stratified by timepoint because of the above evidence that CRHBP effects are time-
dependent. A highly significant interaction was observed between FKBP5 and CRHBP risk 
allele and MSP pain outcome 6 weeks after MVC (p <0.0001, Table 4). For example, 
individuals with two copies of the FKBP5 risk allele and one or more copies of the CRHBP 
risk allele had MSP nearly double the severity of individuals without the additional CRHBP 
risk allele(s) (Table 4, Figure 2 Panel B). This interaction did not reach statistical 
significance at later timepoints, although a similar trend in effect size was observed at the 6 
month timepoint.
 DISCUSSION
Currently little is known about the biological pathways involved in chronic pain 
development following trauma exposure or which individuals are at high risk of developing 
MSP following exposures such as MVC. This study is the second study to identify a genetic 
association between HPA axis-related genes and MSP outcomes after MVC. In our prior 
study using the same dataset, we reported that the same FKBP5 risk alleles predict MSP 
severity six weeks after both MVC and sexual assault.[10] (That sexual assault study did not 
include data from the later follow-up timepoints used in the present analysis.) In the present 
study, haplotypes within another important HPA axis gene, CRHBP, predicted MSP burden 
during the year after MVC, with the adverse effect of a vulnerability allele increasing over 
time. The effect of CRHBP also interacted with FKBP5 vulnerability alleles identified in the 
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previous study, such that individuals with vulnerability alleles at both of these HPA axis 
genes had substantially greater MSP after MVC than individuals with a vulnerability allele 
at only one gene. This finding is consistent with the results of a previous study that found an 
interaction between CRHBP and FKBP5 genes and mental health outcomes following 
childhood trauma[46].
CRH-BP and FK506 binding protein 51 (FKBP5) are key regulatory proteins affecting HPA 
axis function. Neural input into the hypothalamus causes the release of Corticotropin-
Releasing Hormone (CRH), which initiates activation of the HPA axis. CRH-BP has 
complex effects[49; 60], evidence from animal studies suggests that increased CRH-BP 
expression inhibits HPA axis activation[48]. HPA axis activation results in the release of 
cortisol which diffuses through the cell membrane of cells in the body and binds to the 
glucocorticoid receptor (GR)[62]. FKBP5 regulates the sensitivity of the glucocorticoid 
receptor (GR) to cortisol[6]. Higher expression of FKBP5 has been shown to reduce cortisol 
binding affinity of the GR [14] and nuclear translocation of the GR[61] (i.e., result in GR 
resistance to cortisol), with accompanying increased plasma cortisol levels[14; 47].
Available evidence indicates that FKBP5 variants associated with worsened chronic MSP 
outcomes following MVC in the present study cause GR resistance to cortisol [7; 10; 14; 
47]. In contrast, the physiologic effect of CRH-BP variants associated with worsened 
chronic pain outcomes following MVC in the present study are not well understood. To date, 
no studies have identified functional effects of variants in the CRHBP locus[8]. Further 
studies are needed to understand the functional effects of the identified CRHBP variants.
Epistatic interactions such as the interaction observed in the present study between the 
FKBP5 and CRHBP risk alleles are common[42]. This interaction was observed 6 weeks 
after MVC but not at 6 months or 1 year. The time-dependent nature of these interactions 
could be due to decreased power at later timepoints, as more individuals recover and have 
reduced MSP scores. This hypothesis is supported by the fact that the same direction of 
effect was observed at the 6 month and 1 year timepoints, but the effect weaker. Another 
potential contributor to the different effect of these interactions over time is that stress-
related biologic effects are often markedly time-dependent[15].
The results of this study cannot determine to what extent the HPA axis is directly involved in 
the pathogenesis of post-MVC MSP or is a marker for pathobiologic processes mediated by 
other physiologic systems. Several lines of evidence from other studies suggest however that 
the HPA axis may itself have a direct contributing role. First, in a well-elucidated animal 
model of stress-induced hyperalgesia, widespread hyperalgesia was demonstrated to be due 
to the direct effect of persistently elevated levels of glucocorticoids and catecholamines on 
primary sensory afferents[27]. In addition, glucocorticoid systems exert an important 
influence on immune system function, and CRHBP and FKBP5 risk haplotypes may 
influence post-stress outcomes in part via mechanisms which lead to the increased 
production of pro-inflammatory mediators (e.g. cytokines)[17; 50]. Such mediators may 
promote allodynia and hyperalgesia both by sensitizing peripheral and central afferents 
directly[18; 19; 32] and by sensitizing CNS neurons via an afferent feedback mechanism[18; 
19; 32; 56–58]. CRHBP and FKBP5 risk haplotypes may also affect sensory processing after 
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stress exposure by their effect on central nervous system glucocorticoid pathways (e.g. [52; 
55]).
Findings regarding the CRHBP allele evaluated in the present study are consistent with data 
linking this locus with other stress-related neuropsychiatric disorders. CRHBP rs1875999, 
one of the three CRHBP variants comprising the CRHBP H2 haplotype in the present study 
and the only one of these SNPs conserved across multiple mammalian species (http://
genome.ucsc.edu/ Dec. 2013 (GRCh38/hg38) Assembly), has been associated with 
vulnerability to attempting suicide after stress exposure[13; 46] and to stress-related drug 
addiction[28]. CRHBP rs1875999 has also been associated with an increased number of pain 
sites[23]. CRHBP rs1875999 is located in the 3’UTR of the CRHBP gene; this gene region 
functions as a post-transcriptional regulatory region by determining the localization, 
stability, and translational efficiency of a gene transcript[3]. Molecular factors currently 
known to influence protein translation via the 3’UTR include binding by regulatory proteins 
or by microRNA[4; 43]. Examination of the genomic region surrounding the two CRHBP 
SNPs in the 3’UTR identified in this study, do not suggest direct influence of the allele on 
RNA binding protein binding or microRNA binding. However, the Adenylate-uridylate (AU) 
content of the CRHBP 3’UTR is 66 percent (average 3’UTR AU content ~55 percent [41]) 
and there are a number of AU-rich elements (AREs) in the CRHBP 3’UTR[21]. Therefore 
one potential molecular effect mediating the association between CRHBP H2 haplotype and 
chronic post-MVC pain outcomes is that this polymorphism affects CRHBP protein levels 
via modulating regulatory protein binding to ARE regions. Indeed, one such regulatory 
protein, HuD (ELAVL4), has previously been shown to affect neuronal plasticity[40]. 
Further studies are needed to evaluate this hypothesis.
The reasons for a lack of association between NR3C1 and CRHR1 genetic variants and 
chronic MSP are not known. Given the relatively low MAFs for many of the NR3C1 and 
CRHR1 alleles evaluated in comparison to the evaluated CRHBP alleles, it is possible that 
our sample size was underpowered for these alleles. In addition, previous associations 
between NR3C1 variants and post-trauma outcomes have suggested that functional variants 
in this gene affect hypermethylation of the promoter region[11; 33; 59]. Because the genetic 
variants assessed in our study were mostly intronic and downstream of the promoter, it is 
possible that we did not tag alleles responsible for methylation status of NR3C1. If this is the 
case, then lack of adjustment for this important covariate (hypermethylation status) may 
have reduced our power or biased our findings towards the null.
Several limitations should be noted when interpreting the results of this study. First, to avoid 
confounding by population stratification our study only enrolled European Americans. The 
generalizability of our findings to other race/ethnic groups is unknown. Second, results 
regarding the association between the CRHBP allele and post-MVC MSP outcome 
identified in the present study have not been replicated in a second cohort. However, this is 
not a novel finding of a previously unstudied gene locus. Instead this is a finding of an 
association between a stress-related outcome (chronic post-MVC MSP) and a gene locus 
previously associated with other stress-related disorders, in a biologic pathway that has been 
implicated in the pathogenesis of chronic MSP development in both animal and human 
studies. Thus from a Bayesian viewpoint, we believe that the post-test probability of our 
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allele actually contributing to risk of chronic post-MVC MSP exceeds that of a novel 
replicated allele, and that our finding is likely to be a true positive. Finally, another limitation 
is that we enrolled only about half of the potentially eligible participants. The 
generalizability of our results among individuals who declined enrollment is not known. 
These limitations are consistent with other studies enrolling subjects after an acute aftermath 
of trauma in an ethical manner.
 CONCLUSIONS
The results of this study suggest that genetic variants in corticotropin-releasing hormone 
binding protein, a gene affecting glucocorticoid signal transduction, influence the severity of 
pain symptoms experienced one year after MVC trauma. These findings add further 
evidence that physiologic systems which shape stress and neuroimmune responses, such as 
the HPA axis, may play an important role in influencing MSP outcomes after traumatic/
stressful events such as MVC. These findings also suggest that glucocorticoid pathways 
might be a good target of interventions aimed at improving recovery and diminishing 
chronic pain after trauma exposure.
 Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Genomic location and Linkage Disequilibrium Plots of CRHBP, CRHR1, and NR3C1 
polymorphisms analyzed in this study. Color and numbers represent D’ values (dark 
red=high inter-SNP D’; white=low inter-SNP D’).
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Figure 2. 
Trajectories of pain severity by genotype. In panel A, patients are grouped by their CRHBP 
or FKBP5 genotype. CRHBP H2 (+) denotes the presence of at least one H2 risk haplotype; 
FKBP5 rs3800373 (+) denotes presence of the risk allele. In panel B, patients are grouped 
by the combination of their CRHBP and FKBP5 genotypes. CRHBP H2 (+) denotes the 
presence of at least one H2 risk haplotype; FKBP5 rs3800373 (+) denotes the presence of 
two risk alleles.
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Table 1
Baseline characteristics of study participants
Characteristic
Enrolled, n 949
Age, years, mean (SD) 36(13)
Females, n (%) 575(61)
Education, n (%)
8–11 yrs 42(4)
HS 184(19)
Post-HS 57(6)
Some college 311(33)
College 237(25)
Post-college 113(12)
Overall pain, 0–10 NRS, mean (SD)
Past month 0.4(0.5)
ED 5.5(2.4)
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